Ipamorelin vs Epithalon
A comprehensive, data-driven comparison of Ipamorelin (NNC 26-0161) and Epithalon (Epitalon). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | Ipamorelin NNC 26-0161 | Epithalon Epitalon, Epithalone |
|---|---|---|
| FDA Status | Category 2 (pending reclassification) | Not submitted |
| Category | Growth Hormone | Anti-Aging |
| Primary Use | Growth hormone optimization | Anti-aging and longevity research |
| Weight Loss % | N/A | N/A |
| Monthly Cost | $35 - $70/mo | $40 - $80/mo |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Dose | 200-300mcg 2-3x daily | 5-10mg per cycle (10-20 days, 2-3x per year) |
| Frequency | Daily | Cyclical |
| Mechanism | Selective growth hormone secretagogue that binds to ghrelin receptors to stimulate GH release without affecting cortisol or prolactin | Tetrapeptide that may activate telomerase enzyme to lengthen telomeres and potentially extend cellular lifespan |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | Emerging | Emerging |
| Clinical Trial Phase | N/A | N/A |
Key Differences
- 1Ipamorelin is generally more affordable ($35 - $70/mo) compared to Epithalon ($40 - $80/mo).
- 2Ipamorelin is dosed daily, while Epithalon is cyclical.
- 3They belong to different categories: Ipamorelin (Growth Hormone) vs Epithalon (Anti-Aging).
Which Is Better For...
Ipamorelin
More budget-friendly option with lower monthly costs
Epithalon
More convenient dosing schedule (cyclical)
Epithalon
Fewer commonly reported side effects
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| Ipamorelin | $35 - $70/mo | Category 2 (pending reclassification) | Various research labs |
| Epithalon | $40 - $80/mo | Not submitted | Various research labs |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
Ipamorelin works via Selective growth hormone secretagogue that binds to ghrelin receptors to stimulate GH. Epithalon works via Tetrapeptide that may activate telomerase enzyme to lengthen telomeres and potentially extend. They differ in FDA approval status, efficacy data, and cost.
Ipamorelin typically costs $35 - $70/mo, while Epithalon costs $40 - $80/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
Ipamorelin is not FDA-approved (Category 2 (pending reclassification)). Epithalon is not FDA-approved (Not submitted). FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of Ipamorelin include Injection site reactions, Increased hunger, Headache. Common side effects of Epithalon include Injection site reactions, Mild drowsiness, Vivid dreams. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
Ipamorelin is a pentapeptide that selectively stimulates growth hormone release by mimicking ghrelin, the hunger hormone. Unlike many other GH secretagogues, ipamorelin does not significantly increase...
View Full Ipamorelin GuideEpithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) researched primarily in Russia for its potential anti-aging properties. The proposed mechanism involves activation of telomerase, an enzyme that...
View Full Epithalon GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between Ipamorelin and Epithalon should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.